Breast Cancer
BHR is developing Afimoxifene gel, with potential for breast cancer prevention as well as a treatment for cyclic breast pain and other benign breast conditions. A multi-center, Phase 2 trial of Afimoxifene gel vs. oral tamoxifen in women with ductal carcinoma in situ (DCIS) of the breast will be conducted by the National Cancer Prevention Group Consortium starting in the third quarter of 2009. This trial is being coordinated by the National Institutes of Health/National Cancer Institute.
